Compare MMLP & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MMLP | IXHL |
|---|---|---|
| Founded | 2002 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.4M | 97.6M |
| IPO Year | 2002 | 2024 |
| Metric | MMLP | IXHL |
|---|---|---|
| Price | $2.87 | $4.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.5K | ★ 6.5M |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,653,009,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.65 | N/A |
| 52 Week Low | $2.21 | $0.11 |
| 52 Week High | $3.90 | $1.66 |
| Indicator | MMLP | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 96.09 |
| Support Level | $2.50 | $0.32 |
| Resistance Level | $3.05 | N/A |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.00 | 0.25 |
| Stochastic Oscillator | 65.96 | 80.26 |
Martin Midstream Partners LP has a diverse set of operations focused in the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and natural gas liquids marketing, distribution and transportation services. Company operates in four segment Terminalling and storage, Transportation, Sulfur service and Specialty products segment. Majority of the revenue derived from Specialty products segment.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.